Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03143374 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PET Tau - Neurodegenerative Disease Imaging

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Sep 2016 to Aug 23, 2016v15
  2. Primary completion date: Sep 2025 to Sep 2030 Completion date: Dec 2025 to Sep 2030v14 Show 1 more changeShow less
    • Completion date: Dec 2025 to Sep 2030
  3. Re-verified, no change to tracked fieldsv13
  4. Site contact updatedv12
  5. Eligibility criteria shortened, about 87 words Secondary endpoints: details revised at 2 of 2 entriesv11 Show 1 more changeShow less
    • Secondary endpoints: details revised at 2 of 2 entries

    See this version in full on ClinicalTrials.gov ↗

Show 9 earlier versionsHide 9 earlier versions
  1. Primary completion date: Sep 2023 to Sep 2025 Completion date: Dec 2023 to Dec 2025 · Site contact updatedv10 Show 2 more changesShow less
    • Completion date: Dec 2023 to Dec 2025
    • Site contact updated
  2. Interventions: [18F]T807 (Drug) to 18F-AV-1451 (Drug) Study description shortened, about 1 wordv9 Show 1 more changeShow less
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Phase: Not specified to Phase 2/3 Enrollment target: 120 to 300 · Interventions: [18F]T807 (also known as 18F-AV- 1451) (Device) to [18F]T807 (Drug) · Eligibility criteria shortened, about 255 words · 3 morev8 Show 6 more changesShow less
    • Enrollment target: 120 to 300
    • Interventions: [18F]T807 (also known as 18F-AV- 1451) (Device) to [18F]T807 (Drug)
    • Eligibility criteria shortened, about 255 words
    • Secondary endpoints: 1 to 2
    • Site contact updated
    • Study arms: 0 to 1

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Sep 2022 to Sep 2023 Completion date: Dec 2022 to Dec 2023v7 Show 1 more changeShow less
    • Completion date: Dec 2022 to Dec 2023
  5. Trial status: Active, Not Recruiting to Recruiting Site details revisedv6 Show 1 more changeShow less
    • Site details revised
  6. Trial status: Recruiting to Active, Not Recruiting Site details revisedv5 Show 1 more changeShow less
    • Site details revised
  7. Primary completion date: Sep 2019 to Sep 2022 Primary endpoint revised · Completion date: Dec 2021 to Dec 2022 · Secondary endpoint revised · 2 morev4 Show 5 more changesShow less
    • Primary endpoint revised
    • Completion date: Dec 2021 to Dec 2022
    • Secondary endpoint revised
    • Study description shortened, about 8 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  8. Eligibility criteria expanded, about 406 words Site contact updated · Study description expanded, about 4 words · Study title shortened, about 5 wordsv3 Show 3 more changesShow less
    • Site contact updated
    • Study description expanded, about 4 words
    • Study title shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  9. Primary completion date: Sep 2017 to Sep 2019 Completion date: Dec 2019 to Dec 2021v2 Show 1 more changeShow less
    • Completion date: Dec 2019 to Dec 2021
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).
Trial Details
NCT Number NCT03143374
Lead Sponsor University of Pennsylvania
Collaborators: Avid Radiopharmaceuticals
Conditions Neurodegenerative Disease
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov